Please login to the form below

Not currently logged in
Email:
Password:

ChemoCentryx

This page shows the latest ChemoCentryx news and features for those working in and with pharma, biotech and healthcare.

ChemoCentryx surges on phase 3 vasculitis study

ChemoCentryx surges on phase 3 vasculitis study

ChemoCentryx’ complement C5a inhibitor avacopan has outperformed standard corticosteroid therapy in a phase 3 vasculitis trial, causing a spike in its share price and analyst speculation it may have a blockbuster ... ChemoCentryx’ chief executive

Latest news

  • GSK hands back rights to ChemoCentryx drug GSK hands back rights to ChemoCentryx drug

    GSK licensed rights to vercirnon (also known as Traficet-EN and CCX282) in 2010 as an extension to a wide-ranging deal with ChemoCentryx for four anti-inflammatory drugs. ... GSK dropped another drug from the initial collaboration earlier this year, but

  • Takeda files IBD drug vedolizumab in Europe Takeda files IBD drug vedolizumab in Europe

    Growth for vedolizumab and other new entrants such as Johnson &Johnson's interleukin-23 inhibitor Stelara (ustekinumab) and GlaxoSmithKline/ChemoCentryx' vercirnon in Crohn's - and Pfizer's JAK inhibitor tofacitinib in

  • GSK to tackle inflammatory bowel disease

    GSK has exercised an option to further develop ChemoCentryx's Traficet-EN (CCX282-B)  for the treatment of inflammatory bowel disease. ... Under the terms of the collaboration, ChemoCentryx will receive an option exercise fee of $35m and may be

  • Pharma news in brief

    ChemoCentryx will receive an upfront payment of $63.5m in both cash and an equity investment. ... The collaboration covers several projects, including ChemoCentryx's drug, Traficet-EN, which is already in late-stage development for inflammatory bowel

  • A bright start

    The group has formed a strategic alliance with US-based ChemoCentryx to develop and market treatments for various inflammatory disorders in a licensing deal that could be worth up to ... ChemoCentryx is to receive an upfront $63.5m payment comprising

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    In an expansion of their May 2016 licence, Vifor Pharma has gained additional territorial rights from ChemoCentryx to avacopan, a phase III oral inhibitor of the complement 5a receptor (C5aR) for ... In return for the expanded territory, Vifor is paying

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....